Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Editorial

Human papillomavirus vaccine risk and reality

Noni MacDonald, Matthew B. Stanbrook and Paul C. Hébert
CMAJ September 09, 2008 179 (6) 503; DOI: https://doi.org/10.1503/cmaj.081238
Noni MacDonald MD MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Stanbrook MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul C. Hébert MD MHSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2008 Canadian Medical Association

Loudly voiced concerns greeted Canada's school-based human papillomavirus (HPV) vaccine programs last year. This was particularly the case in Ontario, where vaccine uptake was only about 50%, a sharp contrast to over 80% uptake in Nova Scotia and Australia. In comparison, uptake of the hepatitis B vaccine is over 90% in school-based programs across Canada. So why did HPV vaccine uptake fall below expectations, given that the goal is prevention of cervical cancer, a potentially fatal disease?

Cassels1 characterized the vaccine debate as the “just do it” camp, which focuses on averting potential cervical cancer deaths, versus the “what's the hurry” camp, which focuses on residual unknowns such as costs, effectiveness and safety. This debate has been valuable for those who followed it attentively, but some parents and potential vaccine recipients who chose not to participate in the program may have only heard fragments of the discourse.

There are lessons to be learned here for European countries and other Canadian provinces that are poised to launch HPV vaccine programs. Ensuring trust in any vaccine program requires anticipating and proactively addressing concerns of parents and potential vaccine recipients, especially those in the “what's the hurry” camp. Emphasis and data on vaccine safety, vaccine benefits and disease risk are crucial.

Although all new vaccines are studied for effectiveness and safety before licensure, vaccine trial participants often do not represent the general population. And although trials may enrol several thousand participants, this is often too few to detect rare serious adverse effects. This raises legitimate safety concerns among parents and potential recipients.

In this issue, Brotherton and colleagues2 provide compelling evidence that the HPV vaccine is remarkably safe. In Australia, the only serious adverse events noted with careful follow-up of over 260 000 vaccine doses were very rare cases of anaphylaxis (2.6 events per 100 000 doses). There were no cases of anaphylactic shock. All of the girls recovered completely, usually rapidly after receiving epinephrine. In a related commentary, Halsey3 provides further support for the rareness of anaphylaxis and other serious adverse events following administration of millions of doses of this vaccine. These data should provide reassurance to parents and potential recipients who have called for more evidence of the vaccine's safety.

The study by Brotherton and colleagues gives the Canadian public health community an excellent opportunity to restart public discussions about the safety of the HPV vaccine, the precautions taken to mitigate risks if anaphylaxis occurs, and the care taken in surveillance for adverse events following vaccination.4 These school-based vaccine programs require vaccine providers to have the training and equipment needed to manage anaphylaxis and to observe recipients for 15 minutes after vaccination; these are basic requirements for providing vaccination in any setting.4

Public health campaigns must address the fact that parents and potential vaccine recipients see remote health concerns as more easy to ignore than those close at hand. Cervical cancer may seem a remote risk for a teenager, but in Canada an estimated 1300 women will be diagnosed with cervical cancer this year and 380 will die.5 This risk remains despite decades of public health campaigns about the importance of regular screening.

Delaying immunization until a young woman is sexually active may seem a credible alternative, but it is not. HPV infection can occur with the first sexual intercourse, and half of Canada's young women become sexually active by age 16. Adolescent behavioural risk factors are inadequate predictors of future infection with vaccine type HPV.6

Ideally, high rates of HPV immunization would reduce cervical cancer risk for unvaccinated as well as vaccinated women via herd immunity. At present, this is unlikely to happen because both males and females would need to be immunized. Canada and other industrialized countries (except for Australia) have only approved vaccination for females thus far, because studies involving males have not been completed. Hence, for now, only immunized women will be protected.

By publishing these vaccine safety data, CMAJ continues to add to the HPV vaccine discourse. Now it is up to public health and other practitioners to listen carefully and respond to the public's concerns. Respecting every woman's right to decide for herself about the HPV vaccine includes ensuring that this decision is based on a balanced and factual perspective of the competing risks, rather than on ignorance or irrational fears.

Footnotes

  • With the Editorial-Writing Team (Rajendra Kale MD, Barbara Sibbald BJ, Ken Flegel MDCM MSc and Amir Attaran LLB DPhil)

    Competing interests: See www.cmaj.ca/misc/edboard.shtml.

REFERENCES

  1. 1.↵
    Cassels AK. Vaccination against human papilloma virus [letter]. CMAJ 2007;177:1526.
    OpenUrlFREE Full Text
  2. 2.↵
    Brotherton JML, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008;179:525-33.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Halsey NA. The human papillomavirus vaccine and risk of anaphylaxis. CMAJ 2008;179:509-10.
    OpenUrlFREE Full Text
  4. 4.↵
    Public Health Agency of Canada. Canadian Immunization Guide. 7th ed. Ottawa (ON): The Agency; 2006. Available: www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php (accessed 2008 Aug 5).
  5. 5.↵
    Canadian Cancer Society. Canadian Cancer Statistics. Toronto (ON): The Society; 2008. Available: www.cancer.ca/ccs/internet/standard/0,3182,3172_14279__langId-en,00.html (accessed 2008 Aug 5).
  6. 6.↵
    Dempsey AF, Gebremariam A, Koutsky L, et al. Behavior in early adolescence and risk of human papillomavirus infection as a young adult: results from a population-based study. Pediatrics 2008;122:1-7.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 179 (6)
CMAJ
Vol. 179, Issue 6
9 Sep 2008
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human papillomavirus vaccine risk and reality
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human papillomavirus vaccine risk and reality
Noni MacDonald, Matthew B. Stanbrook, Paul C. Hébert
CMAJ Sep 2008, 179 (6) 503; DOI: 10.1503/cmaj.081238

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Human papillomavirus vaccine risk and reality
Noni MacDonald, Matthew B. Stanbrook, Paul C. Hébert
CMAJ Sep 2008, 179 (6) 503; DOI: 10.1503/cmaj.081238
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Accuracy in images
  • Google Scholar

More in this TOC Section

  • Regard sur la santé des personnes noires et le racisme anti-Noirs dans les systèmes de santé au Canada
  • A focus on access to health care in Canada
  • L’avenir de la médecine est ici et vous en êtes la trame narrative
Show more Éditorial

Similar Articles

Collections

  • Topics
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire